Patent ID: 9603864
Date: 2017-03-28
CPC Classifications: A61K,A61P,C07F

Claim:
1. A method for ameliorating or treating a viral infection comprising contacting a cell infected with a virus with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) has the structure: wherein: B wherein R R R R R R R R R R and R 7A is absent or hydrogen; R R R R R R R m is 0 or 1; s is 0, 1, 2 or 3; and Z wherein the virus is selected from the group consisting of MERS-CoV, SARS-CoV, Venezuelan equine encephalitis virus, Chikungunya virus and coronavirus; and when a group is substituted, the group is substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), heteroaryl(alkyl), (heterocycyl)alkyl, hydroxy, alkoxy, acyl, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, azido, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, an amino, a mono-substituted amino group and a di-substituted amino group; and wherein an —N-linked α-amino acid ester derivate refers to an α-amino acid in which a main-chain carboxylic acid group has been converted to an ester group.